Skip to main content
All lobbying clients

NOVOZYMES NORTH AMERICA, INC.

Lobbying client · North Carolina · filed 2025 to 2026

$1,750,000 Reported spend
18 Filings counted
2 Outside firms hired
9 Bills named

Spend is reported income plus in-house expenses across 18 filings. The LDA keeps a separate client record for every registrant that files for a client, so this page adds up 3 records, one per registrant listed below. Records are combined when the client name matches once case, punctuation and endings such as Inc. or LLC are set aside; for a city, county or port the state has to match as well. These filings have also been reported as NOVOZYMES NORTH AMERICA INC.

 Who filed for this client 3

Spend per registrant: fees an outside firm reported, or the costs the client reported for lobbying in-house. The rows add up to the total above.

 Bills named in these filings 9
  • H.R. 2756
    National Biotechnology Initiative Act of 2025
    6 filings
  • H.R. 7366
    Dietary Supplement Regulatory Uniformity Act
    3 filings
  • S. 1387
    National Biotechnology Initiative Act of 2025
    3 filings
  • H.R. 4794
    Dietary Supplements Access Act
    2 filings
  • S. 3172
    A bill to amend the Internal Revenue Code of 1986 to include certain over-the-counter dietary supplement prod…
    2 filings
  • H.R. 1346
    Nationwide Consumer and Fuel Retailer Choice Act of 2025
    1 filing
  • H.R. 4864
    Ethanol for America Act of 2025
    1 filing
  • S. 2591
    Ethanol for America Act of 2025
    1 filing
  • S. 593
    Nationwide Consumer and Fuel Retailer Choice Act of 2025
    1 filing
 Reported by year 2 years
  • 2026 $670,000 7 filings
  • 2025 $1,080,000 11 filings
 Issues lobbied 6

The count is how many filings named that issue area. A filing reports one lump figure covering every issue on it, so the money above cannot be split between them.

 Agencies and chambers lobbied 8
  • HOUSE OF REPRESENTATIVES 17
  • SENATE 17
  • Agriculture, Dept of (USDA) 6
  • Environmental Protection Agency (EPA) 4
  • Food & Drug Administration (FDA) 2
  • White House Office 2
  • Executive Office of the President (EOP) 1
  • U.S. Customs & Border Protection 1
 Recent filings 18 total
Q3 report
NOVOZYMES NORTH AMERICA, INC.
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $110,000 expenses · posted Oct 20, 2026
View → Q3 report
ATLAS CROSSING LLC
3rd Quarter 2026 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2026
View → Q2 report
NOVOZYMES NORTH AMERICA, INC.
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $140,000 expenses · posted Jul 20, 2026
View → Q2 report
ATLAS CROSSING LLC
2nd Quarter 2026 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 20, 2026
View → Q1 report
ATLAS CROSSING LLC
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 20, 2026
View → Q1 report
NOVOZYMES NORTH AMERICA, INC.
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $220,000 expenses · posted Apr 20, 2026
View → Q1 termination
THE RUSSELL GROUP, INC.
1st Quarter 2026 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 8, 2026
View → Q4 report
THE RUSSELL GROUP, INC.
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Jan 20, 2026
View → Q4 report
NOVOZYMES NORTH AMERICA, INC.
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $150,000 expenses · posted Jan 20, 2026
View → Q4 report
ATLAS CROSSING LLC
4th Quarter 2025 (Oct 1 - Dec 31) · House · Senate · $50,000 income · posted Jan 20, 2026
View → Q3 report
ATLAS CROSSING LLC
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2025
View → Q3 report
NOVOZYMES NORTH AMERICA, INC.
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $210,000 expenses · posted Oct 20, 2025
View → Q3 report
THE RUSSELL GROUP, INC.
3rd Quarter 2025 (July 1 - Sep 30) · House · Senate · $50,000 income · posted Oct 20, 2025
View → Q2 report
NOVOZYMES NORTH AMERICA, INC.
2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $270,000 expenses · posted Jul 21, 2025
View → Registration
ATLAS CROSSING LLC
3rd Quarter 2025 (July 1 - Sep 30) · posted Jul 18, 2025
View → Q2 report
THE RUSSELL GROUP, INC.
2nd Quarter 2025 (Apr 1 - June 30) · House · Senate · $50,000 income · posted Jul 15, 2025
View → Q1 report
NOVOZYMES NORTH AMERICA, INC.
1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $150,000 expenses · posted Apr 21, 2025
View → Q1 report
THE RUSSELL GROUP, INC.
1st Quarter 2025 (Jan 1 - Mar 31) · House · Senate · $50,000 income · posted Apr 18, 2025
View →
 Foreign entities disclosed 1
  • NOVOZYMES A/S Denmark named on 1 filing · highest disclosed ownership 100% · largest disclosed contribution $0

Section 7 of the LD-2: a foreign company or government that owns part of the client, pays toward the lobbying, or benefits from it. Figures are the highest single disclosure across these filings, not a sum: the same stake is re-disclosed each quarter.

Keep going

Filings through , the newest posted date on this record. Source: federal Lobbying Disclosure Act filings, synced daily. Money is self-reported by the filer and often rounded. Lobbying is legal, disclosed activity.

Report a problem